血原剂改善了从老鼠大脑和认知功能中粉样β的淋巴清除
Alexander Shirokov1,2, Daria Zlatogosrkaya2, Viktoria Adushkina2
1Institute of Biochemistry and Physiology of Plants and Microorganisms, Russian Academy of Sciences, Prospekt Entuziastov 13, 410049 Saratov, Russia.
International journal of molecular sciences
|December 17, 2024
概括
血原剂 (Pls) 减少大脑中的粉样β (Aβ) 积累,改善阿尔茨海默氏症患者的学习和运动活动.
科学领域:
- 神经科学是一个神经科学.
- 脂质代谢 脂质代谢是什么
- 神经退行性疾病 神经退行性疾病
背景情况:
- 粉样β (Aβ) 积累与衰老和阿尔茨海默病 (AD) 的认知衰退有关.
- 有效的Aβ淋巴清除对于维持大脑平衡至关重要.
- 血原体 (Pls),主要的大脑脂质,显示在缓解AD和认知衰老方面具有潜力.
研究的目的:
- 为了研究等离子体原体对认知功能的影响.
- 为了评估等离子体原体对大脑中的粉样β淋巴清除的影响.
- 在老年和阿尔茨海默氏症小鼠模型中评估等离子素的疗效.
主要方法:
- 给老年小鼠和阿尔茨海默病小鼠模型注射血原体.
- 评估认知功能,包括学习和记忆.
- 测量大脑粉样β水平和评估淋巴清除通路.
- 监测一般运动活动和情绪状态.
主要成果:
- 血原剂降低了大脑Aβ水平,并增强了老年小鼠的学习能力.
- 在AD小鼠中,等离子素改善了Aβ淋巴清除,运动活动,情绪状态和学习.
- 与非常老老鼠相比,老老鼠对认知功能的影响更为明显.
结论:
- 血原体在增强大脑Aβ淋巴清除方面表现有前途.
- Pls可以作为阿尔茨海默病和与年龄相关的认知衰退的治疗策略.
- 对大脑健康和神经退行性疾病治疗的等离子素进行进一步的研究是有必要的.
更多相关视频
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.2K
07:56Author Spotlight: Developing Photo-Stimulation Technology for Toxin Removal in Sleep-Related Brain Diseases
Published on: June 28, 2024
637
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
